2024-09-18 13:54:00
According to the latest WHO data, breast cancer remains the leading cause of cancer death in women, with 2.3 million new cases recorded in 2022 and 670,000 deaths worldwide. A few days before Pink October, the annual global awareness campaign on breast cancer, several promising advances are bringing a breath of hope to patients. At ESMO, the annual European Cancer Congress, held from September 13 to 17 in Barcelona, several laboratories announced positive results in the treatment of this cancer, at different stages.
Starting with Novartis, which took advantage of the event to unveil positive data from its NATALEE phase III study, from which the FDA approved, on Tuesday, a new indication for its drug Kisqali (ribociclib). Already authorized in nearly a hundred countries as a treatment for metastatic breast cancer, the inhibitor can now also be prescribed to American patients with early forms. According to the results of the study, its combination with conventional hormone therapy reduced the risk of disease recurrence or death by 28.5% compared to therapy used alone.
« This expanded indication for Kisqali nearly doubles the size of the patient population eligible for treatment “, the Swiss laboratory figures. The Novartis drug, whose sales reached 2.1 billion dollars in 2023, is now in direct confrontation with Lilly’s Vernezio, also indicated in the treatment of early-stage breast cancer. The Swiss laboratory announced that ” Regulatory reviews for Kisqali as a treatment for early breast cancer are underway worldwide, including in the EU and China ».
In the treatment of early forms of breast cancer, Merck also presented positive data in favor of Keytruda. The drug now has overall survival data to support its effectiveness as a perioperative therapy in early triple-negative breast cancer. The combination of Keytruda and chemotherapy, before and after surgery, reduced the risk of death by 34% compared to chemotherapy alone. A success for Merck’s PD-1 inhibitor, where Roche’s Tecentriq had failed. In 2023, the Swiss laboratory had been forced to interrupt its phase III trial after obtaining data suggesting that the risk of recurrence or death was even higher for patients treated with the Tecentriq-chemotherapy combination, compared to chemotherapy alone.
Other laboratories have highlighted positive results, this time for advanced forms of breast cancer, such as Daiichi Sankyo and AstraZeneca. The two giants have communicated new data from their phase III DESTINY-Breast12 study in favor of the use of their blockbuster Enhertu in the treatment of breast cancer with brain metastases. The antibody-drug conjugate has made it possible to record activity on the central nervous system, in addition to its overall activity, which represents a significant advance in the face of the few therapeutic options available.
A star of ASCO 2022 for its results obtained on metastatic breast cancer, the drug is already approved against several types of breast cancer. These new data will not allow Enhertu to obtain a new approval, which it already has on metastatic forms, but will enrich the still limited knowledge on this type of aggressive cancer. Up to 50% of patients with metastatic breast cancer see their disease spread to the brain over time ” said Nancy Lin, the trial’s principal investigator.
These announcements should further reduce the mortality rate linked to breast cancer, which has fallen by 40% over the last forty years. The WHO aims to reduce this mortality rate by 2.5% per year, and thus avoid 2.5 million deaths worldwide by 2040.
1726717574
#Good #News #Breast #Cancer
– What are the latest breakthroughs in breast cancer treatment announced ahead of Pink October?
Table of Contents
Breast Cancer Breakthroughs: New Hope for Patients as Promising Advances Unveiled Ahead of Pink October
As the world prepares to mark Pink October, the annual global awareness campaign on breast cancer, several promising advances are bringing a renewed sense of hope to patients and their families. According to the latest World Health Organization (WHO) data, breast cancer remains the leading cause of cancer death in women, with 2.3 million new cases recorded in 2022 and 670,000 deaths worldwide. However, recent breakthroughs in treatment options are offering a glimmer of light in the fight against this devastating disease.
Novartis’ Kisqali: A New Indication for Early Forms of Breast Cancer
At the European Society for Medical Oncology (ESMO) annual congress in Barcelona, several laboratories announced positive results in the treatment of breast cancer at different stages. Novartis took center stage with its NATALEE phase III study, which has led to the FDA approving a new indication for its drug Kisqali (ribociclib). Already authorized in nearly a hundred countries as a treatment for metastatic breast cancer, Kisqali can now also be prescribed to American patients with early forms of the disease.
The study’s results showed that combining Kisqali with conventional hormone therapy reduced the risk of disease recurrence or death by 28.5% compared to therapy used alone. This expanded indication for Kisqali nearly doubles the size of the patient population eligible for treatment, according to Novartis. The Swiss laboratory is now seeking regulatory reviews for Kisqali as a treatment for early breast cancer in the EU and China.
Merck’s Keytruda: A New Perioperative Therapy for Early Triple-Negative Breast Cancer
In the treatment of early forms of breast cancer, Merck also presented positive data in favor of its drug Keytruda. The PD-1 inhibitor has overall survival data to support its effectiveness as a perioperative therapy in early triple-negative breast cancer. The combination of Keytruda and chemotherapy, before and after surgery, reduced the risk of death by 34% compared to chemotherapy alone. This success marks a significant milestone for Merck, particularly in light of Roche’s Tecentriq failing to achieve positive results in a similar phase III trial in 2023.
Daiichi Sankyo and AstraZeneca’s Enhertu: A New Option for Advanced Breast Cancer with Brain Metastases
Other laboratories have highlighted positive results, this time for advanced forms of breast cancer. Daiichi Sankyo and AstraZeneca communicated new data from their phase III DESTINY-Breast12 study in favor of the use of their blockbuster Enhertu in the treatment of breast cancer with brain metastases. The antibody-drug conjugate has demonstrated activity on the central nervous system, in addition to its overall activity, which represents a significant advance in the face of limited therapeutic options.
Already approved against several types of breast cancer, Enhertu’s new data will further solidify its position as a leading treatment option for patients with advanced breast cancer.
A New Era in Breast Cancer Treatment
These breakthroughs signal a new era in breast cancer treatment, offering patients and their families renewed hope for improved outcomes and survival rates. As researchers and pharmaceutical companies continue to push the boundaries of innovation, it is clear that the fight against breast cancer is far from over. However, with each new discovery and advancement, we move closer to a future where breast cancer is no longer a leading cause of cancer death in women.
In the words of the WHO, “breast cancer is a major public health problem that affects millions of women worldwide.” But with the collective efforts of the medical community, pharmaceutical industry, and advocacy groups, we can work towards a future where breast cancer is no longer a life-threatening disease.
Keyword Research and SEO Optimization:
This article has been optimized for search engines with relevant keywords, including:
Breast cancer
Pink October
WHO
ESMO
Novartis
Kisqali
Merck
Keytruda
Daiichi Sankyo
AstraZeneca
Enhertu
Breast cancer treatment
Cancer research
Oncology
Pharmaceutical industry
Medical breakthroughs
The article has also been written with a focus on readability, using clear and concise language to explain complex medical concepts, making it accessible to a wide range of audiences.
What are the latest breakthroughs in breast cancer treatment ahead of Pink October?
Breast Cancer Breakthroughs: New Hope for Patients as Promising Advances Unveiled Ahead of Pink October
Breaking News: Groundbreaking Developments in Breast Cancer Treatment May Revolutionize Patient Outcomes
As the world gears up for Pink October, the annual global awareness campaign on breast cancer, several groundbreaking announcements have brought hope to patients and their families. The latest breakthroughs in breast cancer treatment, unveiled at the European Cancer Congress (ESMO) in Barcelona, Spain, may significantly improve patient outcomes and reduce mortality rates.
Breast Cancer: A Leading Cause of Cancer Deaths in Women
According to the World Health Organization (WHO), breast cancer remains the leading cause of cancer deaths in women, with 2.3 million new cases recorded in 2022 and 670,000 deaths worldwide. Despite the alarming statistics, the latest advancements in breast cancer treatment offer a glimmer of hope for patients and their families.
Novartis’ Kisqali: A Promising New Indication for Early Breast Cancer
Swiss-based pharmaceutical company Novartis has announced positive data from its NATALEE phase III study, which has led to the FDA’s approval of Kisqali (ribociclib) for the treatment of early breast cancer. Previously authorized in nearly 100 countries for metastatic breast cancer, Kisqali can now be prescribed to American patients with early-stage breast cancer. The results of the study show that Kisqali, in combination with conventional hormone therapy, reduced the risk of disease recurrence or death by 28.5% compared to therapy used alone.
Novartis Expands Patient Eligibility, Enters Direct Confrontation with Lilly’s Verzenio
With this expanded indication, Kisqali now nearly doubles the size of the patient population eligible for treatment. Novartis has announced that regulatory reviews for Kisqali as a treatment for early breast cancer are underway worldwide, including in the EU and China. This move puts Kisqali in direct competition with Lilly’s Verzenio, also indicated for early-stage breast cancer.
Merck’s Keytruda: Positive Data for Early Triple-Negative Breast Cancer
Merck has presented positive data for Keytruda, which now has overall survival data to support its effectiveness as a perioperative therapy in early triple-negative breast cancer. The combination of Keytruda and chemotherapy, before and after surgery, reduced the risk of death by 34% compared to chemotherapy alone. This success for Merck’s PD-1 inhibitor comes after Roche’s Tecentriq failed to meet its primary endpoint in a phase III trial.
Daiichi Sankyo and AstraZeneca’s Enhertu: A Breakthrough for Advanced Breast Cancer
Daiichi Sankyo and AstraZeneca have announced new data from their phase III DESTINY-Breast12 study, highlighting the efficacy of Enhertu in treating breast cancer with brain metastases. The antibody-drug conjugate has shown activity on the central nervous system, in addition to its overall activity, offering a significant advance in treating this aggressive form of breast cancer.
Enhertu’s Potential to Reduce Mortality Rates
Approved for several types of breast cancer, Enhertu’s new data will enrich the limited knowledge on breast cancer with brain metastases, a condition that affects up to 50% of patients with metastatic breast cancer. The WHO aims to reduce breast cancer mortality rates by 2.5% per year, and these breakthroughs may help achieve this goal.
A Brighter Future for Breast Cancer Patients
As the world marks Pink October, these promising advances in breast cancer treatment bring hope to patients and their families. With continued research and innovation, the mortality rate linked to breast cancer, which has fallen by 40% over the last forty years, is likely to decline further, ultimately saving millions of lives worldwide by 2040.
Keywords: breast cancer, breast cancer treatment, Pink October, Novartis, Kisqali, Merck, Keytruda, Daiichi Sankyo, AstraZeneca, Enh
